ADMA Biologics Balance Sheet Health
Financial Health criteria checks 6/6
ADMA Biologics has a total shareholder equity of $231.9M and total debt of $101.3M, which brings its debt-to-equity ratio to 43.7%. Its total assets and total liabilities are $390.6M and $158.7M respectively. ADMA Biologics's EBIT is $117.7M making its interest coverage ratio 7.8. It has cash and short-term investments of $86.7M.
Key information
43.7%
Debt to equity ratio
US$101.33m
Debt
| Interest coverage ratio | 7.8x |
| Cash | US$86.71m |
| Equity | US$231.89m |
| Total liabilities | US$158.73m |
| Total assets | US$390.62m |
Recent financial health updates
Is ADMA Biologics (NASDAQ:ADMA) Using Too Much Debt?
Jul 17
Is ADMA Biologics (NASDAQ:ADMA) A Risky Investment?
Apr 04We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt
Oct 25We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt
Jun 10ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt
Jun 01Recent updates
ADMA Biologics, Inc.'s (NASDAQ:ADMA) 27% Price Boost Is Out Of Tune With Revenues
Oct 09ADMA Biologics: Riding High On ASCENIV's Success
Oct 02ADMA Biologics, Inc.'s (NASDAQ:ADMA) Intrinsic Value Is Potentially 57% Above Its Share Price
Sep 06ADMA Biologics' (NASDAQ:ADMA) Strong Earnings Are Of Good Quality
Aug 16ADMA Biologics: A Compelling GARP Stock For Biotech Investors
Jul 27ADMA Biologics, Inc. (NASDAQ:ADMA) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Jul 24Is ADMA Biologics (NASDAQ:ADMA) Using Too Much Debt?
Jul 17Is ADMA Biologics, Inc. (NASDAQ:ADMA) Trading At A 43% Discount?
May 30ADMA Biologics, Inc. Just Beat EPS By 45%: Here's What Analysts Think Will Happen Next
May 13Giving ADMA Biologics A Well-Deserved 'Booyah'
May 12ADMA Biologics, Inc.'s (NASDAQ:ADMA) Prospects Need A Boost To Lift Shares
May 08Is ADMA Biologics (NASDAQ:ADMA) A Risky Investment?
Apr 04Rising Margins And Product Promise Drive ADMA Biologics Forward (Rating Upgrade)
Apr 03ADMA Biologics: On A Roll Entering 2024
Jan 19Is There An Opportunity With ADMA Biologics, Inc.'s (NASDAQ:ADMA) 50% Undervaluation?
Jan 09ADMA Biologics, Inc. (NASDAQ:ADMA) Surges 30% Yet Its Low P/S Is No Reason For Excitement
Jan 09We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt
Oct 25We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt
Jun 10The Market Doesn't Like What It Sees From ADMA Biologics, Inc.'s (NASDAQ:ADMA) Revenues Yet
May 12ADMA Biologics: Strong Growth Is Clearing The Path To Profitability
Aug 21ADMA Biologics GAAP EPS of -$0.07, revenue of $33.9M
Aug 10ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt
Jun 01ADMA Biologics: A Path To Profits Looks Clear
May 12ADMA: Pertinent Updates
Apr 18ADMA Biologics' 2021 Numbers Showed Continued Strong Execution
Mar 29Financial Position Analysis
Short Term Liabilities: ADMA's short term assets ($318.2M) exceed its short term liabilities ($44.9M).
Long Term Liabilities: ADMA's short term assets ($318.2M) exceed its long term liabilities ($113.8M).
Debt to Equity History and Analysis
Debt Level: ADMA's net debt to equity ratio (6.3%) is considered satisfactory.
Reducing Debt: ADMA's debt to equity ratio has reduced from 229.1% to 43.7% over the past 5 years.
Debt Coverage: ADMA's debt is well covered by operating cash flow (84.9%).
Interest Coverage: ADMA's interest payments on its debt are well covered by EBIT (7.8x coverage).